Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SPRY · Entity 883 | Director · President and CEO | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2036-09-30 | Direct | 1,036,923 |
Reported balance
After 2026-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 1,036,923 · Balance 1,036,923 F1: 25% of the shares subject to the option vest on July 7, 2027, and the remaining shares will vest monthly thereafter over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vest on July 7, 2027, and the remaining shares will vest monthly thereafter over three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 20:24 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 1,036,923 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0002135296-26-000009 · form4-10052026_081042.xml · derivative · entry 1 Casale Donn · CIK 0002135296 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,036,923 Underlying: Common Stock · 1,036,923 shares Expires 2036-09-30 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on July 7, 2027, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 898,456 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0002135296-26-000007 · form4-07022026_040714.xml · derivative · entry 1 Casale Donn · CIK 0002135296 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 898,456 Underlying: Common Stock · 898,456 shares Expires 2036-06-30 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on June 1, 2027, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.